Researchers developed a novel gene therapy platform that successfully restored muscle function in preclinical models of Duchenne muscular dystrophy by delivering full-length mRNA of the DMD gene via engineered extracellular vesicles. The treatment showed improved muscle strength, endurance, and function without serious side effects.
SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Biomedical Engineering·DateJun 11, 2026
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
Researchers at Sanford Burnham Prebys have developed a new method to generate more and potent skeletal muscle progenitor cells. The study found that blocking the activity of Janus kinase 2 (JAK2) yields a twofold increase in cell yield, while also delivering more mature and effective cells for regenerative medicine treatment.
SourceSanford Burnham Prebys·JournalStem Cell Reports·TypeExperimental study·DateOct 30, 2025
Scientists have discovered that MYOD protein can act as a gene silencer, clearing out old 'furniture' to reset the cell's identity. This finding challenges dogma and opens up new avenues for understanding cellular reprogramming and regenerative medicine therapies.
SourceSanford Burnham Prebys·JournalGenes & Development·TypeExperimental study·DateAug 8, 2025
A new study suggests that marbling of fat inside muscles is a strong indicator of poor health, including obesity, Type 2 diabetes, and neuromuscular disorders. The research found that intramuscular fat acts as a physical barrier obstructing muscle healing and regeneration.
SourceUniversity of Florida·JournalCell Reports·TypeExperimental study·DateJul 28, 2025
The study found disordered kidney metabolism contributes to DM1 symptoms, including muscle weakness and impaired energy use. The kidney is identified as a site of underlying cell dysfunction contributing to the disease.
SourceMassachusetts General Hospital·JournalNature Communications·DateMar 7, 2025
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
A new study reveals a promising therapy using antimiRs to treat myotonic dystrophy type 1 (DM1), a genetic disorder caused by abnormally high CTG repeats in the DMPK gene. The treatment increased MBNL1 levels and improved muscle cell functions, reducing disease symptoms.
SourceGermans Trias i Pujol Research Institute·JournalScience Advances·TypeExperimental study·DateOct 14, 2024
Researchers have discovered a gene responsible for some inherited retinal diseases, which damage the retina and threaten vision. The study identified the UBAP1L gene as a cause of different forms of retinal dystrophy, including maculopathy and cone-rod dystrophy, affecting central and night vision.
SourceNIH/National Eye Institute·JournalJAMA Ophthalmology·TypeCase study·DateSep 26, 2024
Researchers at UCL Institute of Ophthalmology have revealed the molecular mechanisms behind FECD, a leading cause of vision loss in older adults. The study found that extreme genetic instability plays a key role in the disease's progression.
SourceUniversity College London·JournalEBioMedicine·DateSep 19, 2024
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
Researchers at Karolinska Institutet successfully used gene therapy to improve vision in 11 out of 12 patients with Bothnia dystrophy, a form of hereditary blindness. The treatment involved injecting a specially designed virus under the retina, which produced normal protein and restored visual function.
SourceKarolinska Institutet·JournalNature Communications·DateSep 10, 2024
Researchers have developed three new cellular models of myotonic dystrophy type 1 that accurately represent the clinical diversity of the disease. The models show great heterogeneity in genetic expansion and molecular alterations, making them suitable for studying pathophysiology and testing therapeutic options.
SourceGermans Trias i Pujol Research Institute·JournaliScience·TypeExperimental study·DateJun 20, 2024
A research team from Université Laval has identified a method to save corneal cells from death using healthy mitochondria, reducing mortality rates from 60% to 10%. This approach demonstrates high therapeutic potential for mitochondrial injection, which could maintain vision without transplantation if diagnosed at an early stage.
SourceUniversité Laval·JournalScientific Reports·DateApr 14, 2023
Researchers at Massachusetts General Hospital developed a genetic therapy to correct myotonic dystrophy in mice by targeting the abnormal splicing of the Clcn1 gene. The treatment restored muscle strength and corrected muscle stiffness, reversing muscle fiber type transitions.
SourceMassachusetts General Hospital·JournalNature Communications·TypeExperimental study·DateApr 13, 2023
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers found that platelet depletion increased amyloid plaque size and neuronal damage in APP-PS1 mice. However, platelets may have a beneficial role in limiting plaque growth and attenuating neuritic dystrophy at advanced stages of Alzheimer's disease.
SourceImpact Journals LLC·JournalAging-US·TypeExperimental study·DateFeb 15, 2023
A study using a mouse model of myotonic dystrophy found that GABA receptor sensitivity is linked to the disorder's central nervous system symptoms, including excessive daytime sleepiness. The researchers suggest that drugs like flumazenil, which counteract benzodiazepines, may work against DM's prolonged sleep and fatigue.
Researchers at the University of Maine used zebrafish to test the effectiveness of neuromuscular electrical stimulation (NMES) on muscle strength and structure. The study found that only one NMES regimen, endurance neuromuscular stimulation (eNMES), improved muscle health when combined with an antioxidant and a specific receptor.
A clinical trial at UC Davis Health showed that cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy, stopping deterioration of upper limb and heart functions. The therapy appears to be safe and effective in improving skeletal muscle and cardiac function.
SourceUniversity of California - Davis Health·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateMar 10, 2022
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Researchers at EPFL's School of Life Sciences discovered that blocking sphingolipid synthesis can reverse the symptoms of Duchenne muscular dystrophy, including loss of muscle function and inflammation. This study identifies sphingolipid inhibition as a potential treatment for muscular dystrophies.
SourceEcole Polytechnique Fédérale de Lausanne·JournalScience Advances·DateJan 28, 2022
The Nixon Visions Foundation has given a significant gift to support studies of the PRPH2 gene linked to macular dystrophy and boost stem cell research aimed at developing early diagnosis and a cure for this devastating genetic eye disease. Researchers hope to make a tremendous impact on people with this inherited eye disease.
Researchers at the University of Oregon used CRISPR-Cas9 gene editing to target a specific mutation causing Fuchs' corneal dystrophy, preserving endothelial cell density and function. The study lays the groundwork for future research on using this technique to treat genetic disorders in post-mitotic cells.
SourceUniversity of Oregon·TypeExperimental study·DateAug 3, 2021
Researchers have identified a new blindness gene, IFT122, associated with inherited retinal dystrophy in dogs. The discovery has significant implications for understanding the genetic background of the disease and developing novel treatments.
SourceUniversity of Helsinki·JournalHuman Genetics·DateMar 2, 2021
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers from TalTech have made a groundbreaking discovery linking CTG repeat expansion to Fuchs' corneal dystrophy, a common eye disease affecting millions. The study reveals changes in TCF4 expression levels in patients with the disease, paving the way for potential treatment strategies.
SourceEstonian Research Council·JournalScientific Reports·DateJan 13, 2021
Researchers demonstrate that one dose of RNA-targeting CRISPR-Cas9 gene therapy can nearly completely reverse symptoms in a mouse model of myotonic dystrophy, reducing toxic RNA buildup by over 50%. This approach holds promise for treating other genetic diseases caused by repetitive RNA buildup.
SourceUniversity of California - San Diego·JournalNature Biomedical Engineering·DateSep 14, 2020
Researchers at the University of Nottingham have discovered a potential treatment for myotonic dystrophy by inhibiting the CDK12 molecule. The study found that inhibiting this molecule reduces the symptoms of the condition, suggesting a possible route to therapy.
SourceUniversity of Nottingham·JournalScience Translational Medicine·DateApr 29, 2020
A study published in Developmental Cell reveals that myotonic dystrophy's genetic abnormalities lead to the overproduction of an alternative-splicing factor that regulates protein processing. This triggers abnormal splicing of proteins essential for heart cell function, causing cardiac conduction defects.
SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalDevelopmental Cell·DateFeb 27, 2020
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
Jayne S. Weiss, MD, has been awarded the 2020 Castroviejo Award for her outstanding work on corneal dystrophies, particularly Schnyder corneal dystrophy. Her research focuses on genetic mapping and pathophysiology of corneal diseases, making significant contributions to the field.
SourceLouisiana State University Health Sciences Center·DateOct 22, 2019
Researchers have successfully developed and tested a gene therapy approach using CRISPR-Cas9 technology to treat Steinert's myotonic dystrophy, a devastating neuromuscular disease. The study showed that the expanded CTG triplet repeat in the DMPK gene was 'cut' and removed from the gene, reducing toxic RNA aggregates in muscle cells.
SourceAFM-Téléthon·JournalMolecular Therapy·DateJun 25, 2019
Researchers at Scripps Research have developed a potential drug that targets the genetic defect causing myotonic dystrophy type 1, a disease affecting 1 in 2,500 people. The therapy, called Cugamycin, improves muscle defects without harming healthy gene transcripts.
SourceScripps Research Institute·JournalProceedings of the National Academy of Sciences·DateApr 1, 2019
A new editorial and free resource clarify corneal dystrophy diagnoses based on corrected medical literature, with the International Committee for Classification of Corneal Dystrophies providing an updated standard classification. The IC3D nomenclature has become internationally accepted.
SourceLouisiana State University Health Sciences Center·JournalAmerican Journal of Ophthalmology·DateNov 7, 2018
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
Researchers have identified genetic factors that cause congenital myotonic dystrophy, a debilitating muscle disorder. They developed specialized mouse models to test potential drug therapies and found severe RNA misprocessing as a major cause of the disease.
SourceUniversity of Florida·JournalGenes & Development·DateJul 11, 2017
Researchers discovered three novel genetic mutations associated with Fuchs endothelial corneal dystrophy, increasing the number of known risk factors fourfold. The study also revealed sex-specific differences in genetics and found that these genes can predict disease risk with approximately 78% accuracy.
SourceCase Western Reserve University·JournalNature Communications·DateApr 11, 2017
Researchers found that treatments don't fit a 'one size fits all' model for patients with myotonic dystrophy type 1. Targeted therapies were more effective when matched to individual symptoms, with 29% of patients benefiting from treatments such as CPAP and modafinil.
SourceIOS Press·JournalJournal of Neuromuscular Diseases·DateJan 13, 2017
A new, minimally invasive procedure called Descemet stripping has shown promise in treating Fuchs endothelial dystrophy (FED), a common eye disease. The procedure restored clear vision to three out of four patients without the need for corneal transplants.
SourceUniversity of Chicago Medical Center·JournalCornea·DateJul 13, 2016
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
A joint research group found RNA abnormalities in the sodium channel in the heart as the cause of heart arrhythmia in myotonic dystrophy. This discovery will help prevent death and develop new treatments for the disease. Abnormalities in RNA splicing lead to various conditions, including cardiac sodium channel dysfunction.
SourceOsaka University·JournalNature Communications·DateJun 15, 2016
Myotonic dystrophy causes wasting of skeletal muscles and arrhythmia due to mutated RNA sequences that alter gene regulation. Researchers identify altered SCN5A splicing as key factor in cardiac dysfunctions, paving way for potential treatment restoration of normal heart function.
SourceINSERM (Institut national de la santé et de la recherche médicale)·JournalNature Communications·DateApr 20, 2016
A new study has pinpointed the symptoms of rare myotonic dystrophy type 2 (DM2) that are most important to patients. The research, published in Neurology, found that fatigue and pain were key concerns for DM2 patients.
SourceUniversity of Rochester Medical Center·JournalNeurology·DateNov 18, 2015
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
Researchers have pinpointed the genetic cause of a rare form of blindness, which can present itself as a key-hole shaped defect in the eye. The miR-204 gene mutation has been linked to inherited retinal dystrophy associated with ocular coloboma.
SourceUniversity of Manchester·JournalProceedings of the National Academy of Sciences·DateJun 23, 2015
A potential treatment for myotonic muscular dystrophy has been identified, using an experimental drug that improves muscle function and reduces symptoms in mice. The therapy targets excessive activity of a cellular protein called TWEAK and its receptor Fn14, which correlates with disease severity.
SourceUniversity of Virginia Health System·JournalHuman Molecular Genetics·DateMar 18, 2015
Researchers found that myotonic dystrophy type 1 disrupts the normal control of gene expression in heart tissue, specifically affecting microRNAs. This disruption leads to abnormal protein activity, resulting in disease symptoms such as heart malfunction and death.
SourceBaylor College of Medicine·JournalCell Reports·DateJan 9, 2014
Researchers at Scripps Research Institute have discovered the atomic-level structure of a genetic defect causing myotonic dystrophy type 2, allowing them to design compounds that improve disease-associated defects in treated cells. The study's findings hold promise for treating this rare form of muscular dystrophy.
SourceScripps Research Institute·JournalACS Chemical Biology·DateJan 2, 2014
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers found aberrant splicing changes the form of an enzyme involved in metabolism, leaving slow muscle fibers unable to sustain exercise. This discovery may explain the muscle wasting seen in myotonic dystrophy, a disease characterized by abnormal CTG repeats.
SourceBaylor College of Medicine·JournalProceedings of the National Academy of Sciences·DateJul 29, 2013
Researchers at the University of Illinois have developed a small molecule that breaks up protein-RNA clusters causing muscular dystrophy, offering hope for treatment. The compound targets only the repeating RNA sequence, increasing regulatory activity and breaking up disease-causing clusters.
SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalACS Chemical Biology·DateMay 1, 2013
A novel drug delivery strategy has been shown to neutralize mutant RNA toxicity and eliminate myotonia symptoms in mice with myotonic dystrophy. The approach uses antisense oligonucleotides and peptide-linked morpholino oligonucleotides to target the disease-causing mutation.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateFeb 21, 2013
Research reveals that the amount of protein in solution determines the formation of fibrils, which can lead to cell death. Developing treatments for diseases caused by protein aggregation is a possibility with this new knowledge.
SourceAarhus University·JournalJournal of Biological Chemistry·DateOct 15, 2012
Researchers from IRCM, MIT, USC, and Illumina have made a significant breakthrough in the fight against muscular dystrophies, particularly myotonic dystrophy. The study provides insights into the role of muscleblind-like proteins in causing the disease and has potential applications for diagnostic tools and treatment.
SourceInstitut de recherches cliniques de Montreal·JournalCell·DateSep 12, 2012
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A new mouse model has reproduced key cognitive and behavioral symptoms of myotonic dystrophy, a disease marked by progressive muscle wasting and weakness. The study reveals that molecular missteps disrupt brain function, causing toxic RNAs to produce incorrect proteins in the brain.
Researchers have reversed symptoms of myotonic muscular dystrophy in mice by targeting and eliminating toxic RNA in muscle cells. The treatment approach has shown significant promise, reducing symptoms by up to one year in a mouse model.
SourceUniversity of Rochester Medical Center·JournalNature·DateAug 1, 2012
A new study reveals that myotonic dystrophy patients prioritize fatigue, mobility, and sleep problems over symptoms like myotonia, which are often considered hallmark symptoms. Researchers have developed a patient-reported outcome measure to better evaluate the impact of experimental therapies on patients' lives.
SourceUniversity of Rochester Medical Center·JournalNeurology·DateJul 25, 2012
Researchers have identified a genetic factor called a trinucleotide repeat as a strong predictor of Fuchs' dystrophy. The study found that unusually long segments of repeated DNA nucleotides in the TCF4 gene cause havoc, impacting the coding of the protein.
Apple Watch Series 11 (GPS, 46mm)
Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.
Researchers found that corneal thickening occurs in FECD patients before swelling is observed, necessitating regular monitoring and potential surgical intervention. The study's findings have the potential to improve patient care for Fuchs corneal dystrophy.
SourceCase Western Reserve University·JournalArchives of Ophthalmology·DateApr 9, 2012
A study found that invasive treatment strategies, including heart testing and pacemaker implantation, can increase survival rates for patients with myotonic dystrophy type 1. The treatment approach resulted in a lower incidence of sudden death and improved overall survival.
Myotonic dystrophy is caused by a mutation that causes toxic RNA to accumulate in cells. Antisense oligonucleotides have been shown to be effective in cell culture and mice by degrading the toxic RNA. The treatment will need to be refined for systemic delivery to patients with myotonic dystrophy.
SourceBaylor College of Medicine·JournalProceedings of the National Academy of Sciences·DateFeb 27, 2012
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
Researchers designed a series of small molecules that target an RNA defect causing myotonic dystrophy type 1. These compounds improve biological defects in cell culture and animal models by more than 40 percent.
SourceScripps Research Institute·JournalJournal of Allergy and Clinical Immunology·DateFeb 22, 2012
A new surgical strategy using a single donor cornea can successfully treat two patients with different corneal diseases, such as Fuchs' dystrophy and keratoconus. The approach may nearly double the available corneal tissue supply and make timely treatment available to many more patients.
SourceAmerican Academy of Ophthalmology·JournalOphthalmology·DateFeb 1, 2011
Researchers at the University of Rochester Medical Center found that mexiletine is effective in alleviating myotonia, a central symptom of myotonic dystrophy. The medication reduces muscle stiffness and relaxation time by 38-59% in patients with the condition.
SourceUniversity of Rochester Medical Center·JournalNeurology·DateMay 4, 2010
Scientists studying fruit flies have discovered a critical step in fly vision that is also linked to human retinal dystrophies, which cause visual impairments or blindness. The study's findings suggest that using flies as a model organism can lead to the development of new therapies for treating human retinal degeneration.
SourceJohns Hopkins Medicine·JournalCurrent Biology·DateFeb 16, 2010
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
Researchers at the University of Oregon and University of Rochester discovered a compound that reverses genetic defects in RNA leading to type 1 myotonic dystrophy. The compound, pentamidine, disrupts complexes formed by expanded repeats and protein molecules, allowing proper splicing errors to be rescued.
SourceUniversity of Oregon·JournalProceedings of the National Academy of Sciences·DateNov 6, 2009
Researchers found a synthetic molecule that breaks up deposits of toxic genetic material and re-establishes cellular activity disrupted by myotonic dystrophy. The treatment could restore muscle function in people with the disease.
SourceUniversity of Rochester Medical Center·JournalScience·DateJul 16, 2009
A multicenter study has identified risk factors for sudden death in people with myotonic dystrophy type 1, a common form of muscular dystrophy. The study found that patients with significant ECG abnormalities were at a 3.5 times higher risk of sudden death, while those with atrial arrhythmias had a 5 times higher risk.
SourceIndiana University·JournalNew England Journal of Medicine·DateJun 18, 2008
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers at the University of Rochester Medical Center have identified a synthetic RNA-based molecule that eliminates myotonia, a symptom of muscular dystrophy, in mice. The study restored normal muscle function by re-establishing a critical cellular mechanism that controls electrical activity in muscles.
SourceUniversity of Rochester Medical Center·JournalJournal of Clinical Investigation·DateNov 15, 2007
Researchers at the University of Oregon have identified the normal functioning of an RNA-regulating protein called muscleblind, which helps explain how myotonic dystrophy disease occurs. The study found that muscleblind binds to both normal and toxic forms of RNA, highlighting a key clue to understanding the disease.